126 related articles for article (PubMed ID: 31146111)
1. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract][Full Text] [Related]
2. The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.
Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
[TBL] [Abstract][Full Text] [Related]
3. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of
Li C; Zhang G; Wang Y; Chen B; Li K; Cao L; Ren C; Wen L; Jia M; Mok H; Lai J; Xiao W; Li X; Liao N
Oncol Lett; 2022 Feb; 23(2):68. PubMed ID: 35069877
[TBL] [Abstract][Full Text] [Related]
5. Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients.
Wen L; Zhang G; Ren C; Li X; Mok H; Jia M; Wang Y; Chen B; Li K; Cao L; Li C; Xiao W; Lai J; Lin J; Wei G; Li Y; Zhang Y; Chen X; Liao N
Cancer Manag Res; 2021; 13():3055-3065. PubMed ID: 33854375
[TBL] [Abstract][Full Text] [Related]
6. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.
Zhang G; Wang Y; Chen B; Guo L; Cao L; Ren C; Wen L; Li K; Jia M; Li C; Mok H; Chen X; Wei G; Lin J; Zhang Z; Hou T; Han-Zhang H; Liu C; Liu H; Liu J; Balch CM; Meric-Bernstam F; Liao N
Ann Transl Med; 2019 Apr; 7(8):179. PubMed ID: 31168460
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of
Cao L; Ren C; Zhang G; Li X; Chen B; Li K; Li C; Mok H; Wang Y; Wen L; Jia M; Wei G; Lin J; Liao N
DNA Cell Biol; 2022 May; 41(5):521-538. PubMed ID: 35475703
[No Abstract] [Full Text] [Related]
8. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
Lin X; Lin X; Guo L; Wang Y; Zhang G
Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
[TBL] [Abstract][Full Text] [Related]
9. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of cell cycle-related genes in HR+/HER2- breast cancer.
Lai J; Chen B; Li Y; Lin X; Li M; Liu J; Liao N
Breast Cancer; 2022 Jan; 29(1):121-130. PubMed ID: 34449047
[TBL] [Abstract][Full Text] [Related]
11. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
12. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
13. Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients.
Huang Y; Liu J; Zhu X
Digit Health; 2022; 8():20552076221133699. PubMed ID: 36312851
[TBL] [Abstract][Full Text] [Related]
14. Concomitant
Lin XY; Guo L; Lin X; Wang Y; Zhang G
J Breast Cancer; 2023 Aug; 26(4):363-377. PubMed ID: 37565929
[TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
16. KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Liu X; Qiu R; Xu M; Meng M; Zhao S; Ji J; Yang Y
Breast Cancer Res Treat; 2021 Sep; 189(2):347-361. PubMed ID: 34240274
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Role of
Hwang KT; Kim BH; Oh S; Park SY; Jung J; Kim J; Choi IS; Jeon SY; Kim WY
J Breast Cancer; 2019 Dec; 22(4):548-561. PubMed ID: 31897329
[TBL] [Abstract][Full Text] [Related]
18. Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.
Lan Y; Zhao E; Luo S; Xiao Y; Li X; Cheng S
Breast Cancer Res Treat; 2019 May; 175(1):91-104. PubMed ID: 30739230
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Rare Novel KMT2C Mutation That Presents with Schizophrenia in a Multiplex Family.
Chen CH; Huang A; Huang YS; Fang TH
J Pers Med; 2021 Nov; 11(12):. PubMed ID: 34945726
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
Kurozumi S; Joseph C; Sonbul S; Aleskandarany MA; Pigera M; Alsaleem M; Alsaeed S; Kariri Y; Nolan CC; Diez-Rodriguez M; Johnston S; Mongan NP; Fujii T; Shirabe K; Martin SG; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2018 Nov; 172(1):61-68. PubMed ID: 30056565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
